Supernus Pharmaceuticals to Participate in Major Health Conference
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), based in Rockville, Maryland, is making noteworthy strides in the biopharmaceutical sector, particularly in therapies for central nervous system (CNS) diseases. The company's President and CEO, Jack A. Khattar, is scheduled to be part of a pivotal fireside chat at the TD Cowen 45th Annual Health Care Conference.
Conference Details and Importance
This exciting event is set to take place on a Monday morning where Mr. Khattar will share insights about Supernus’s mission and future direction. Participation in such conferences is crucial as it allows the company to connect with investors, provide updates on product development, and showcase its commitment to advancing CNS treatment options.
Investor Engagement During the Conference
Investors who wish to meet with the Supernus leadership team can coordinate arrangements through the TD Cowen conference staff. Moreover, to ensure accessibility, a live audio webcast of the conversation will be made available. This allows stakeholders to participate virtually and stay informed about the company’s strategic initiatives.
Accessing the Webcast and Future Presentations
The live audio stream can be reached through Supernus's Investor Relations section on their website. Additionally, those interested will be able to access an archived version of the webcast for 60 days after the event, ensuring that no one misses out on important updates regarding Supernus's advancements in the field.
About Supernus Pharmaceuticals
Founded with a focus on developing therapeutic solutions for CNS disorders, Supernus specializes in a broad portfolio of products. These treatments effectively manage conditions such as ADHD, Parkinson's disease dyskinesia, epilepsy, and more. The company is not only committed to enhancing existing therapies but is also actively working on novel candidates aimed at addressing unmet needs in areas like depression and migraine management.
Current Product Portfolio and Developments
A standout characteristic of Supernus is its extensive experience in neuroscience, which includes state-of-the-art clinical programs. The company ensures that its portfolio is strengthened through ongoing research aiming to launch new treatments for CNS disorders currently lacking optimal solutions. As the biopharmaceutical landscape evolves, Supernus remains dedicated to confronting challenges head-on and leveraging innovative research methodologies.
Contact Information for Investors
For additional inquiries, interested parties can connect with key personnel at Supernus Pharmaceuticals. Jack A. Khattar, as well as Timothy C. Dec, the Senior Vice President and CFO, can be reached directly at their main office. Investor relation inquiries can be further directed to Peter Vozzo from ICR Healthcare for more personalized engagement.
Contact Details
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Frequently Asked Questions
1. What is the focus of Supernus Pharmaceuticals?
Supernus Pharmaceuticals specializes in developing treatments for central nervous system diseases.
2. When will the fireside chat take place?
The fireside chat is scheduled for a Monday morning during the TD Cowen Annual Health Care Conference.
3. How can investors access the webcast?
Investors can access the live audio webcast through Supernus's Investor Relations website.
4. Who else is involved in Supernus’s leadership?
Timothy C. Dec serves as the Senior Vice President and CFO.
5. What types of conditions does Supernus's portfolio treat?
The portfolio includes treatments for ADHD, Parkinson’s disease, epilepsy, and chronic migraine, among others.
